<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406480</url>
  </required_header>
  <id_info>
    <org_study_id>7344</org_study_id>
    <nct_id>NCT04406480</nct_id>
  </id_info>
  <brief_title>Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis</brief_title>
  <acronym>PRENATEX</acronym>
  <official_title>Contribution of the Exome Sequencing in Antenatal Period Behind Ultrasound Features Suggestive of a Rare Genetic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital malformations concern 3% of pregnancies; most of them can be seen during
      pregnancy. For some malformations, an invasive sample (trophoblast biopsy or amniocentesis)
      is proposed to search a chromosomal abnormality by the technique of DNA chip. However, some
      strongly suggestive signs of a genetic (and not chromosomal) pathology have a very low
      diagnostic rate with this technique. In the absence of an etiological diagnosis, the
      prognosis for the unborn child is very difficult to assess, as we can't know if the fetal
      malformation is really isolated or associted to other unseen features as part of a syndromic
      condition.

      For some malformations strongly suggestive of a genetic condition, we propose to realize an
      exome (i.e. all coding parts of the genome) sequencing of the trio (child and the 2 parents)
      with a delivery time compatible with the emergency situation of a pregnancy (6 weeks
      maximum). We will apply bioinformatics filters to analyse only genes known to be involved in
      the malformation present in the unborn child and thus avoid the identification of variants in
      unrelated genes. These lists of genes have been previously validated by the Rare Disease
      Health Sectors and the affiliated diagnostic laboratories. The selected malformations are: 1)
      anomalies of the central nervous system (microcephaly (&lt;- 2DS) with anomalies of gyration,
      anomalies of the posterior fossa, anomalies of the midline except agenesis of the corpus
      callosum), 2) ophthalmological anomalies (microphthalmia, hyperplasia vitreous) and 3) renal
      abnormalities (large hyperechoic kidneys).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care</measure>
    <time_frame>13 months</time_frame>
    <description>Comparison of the number of genetic diagnoses made by exome sequencing and by CGH-array.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on pregnancy management and/or postnatal child care due to an etiological diagnosis</measure>
    <time_frame>13 months</time_frame>
    <description>Percentage of antenatal and/or postnatal fetus/child care modified by the molecular result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility study of carrying out exome sequencing in the antenatal period in terms of time to deliver results</measure>
    <time_frame>13 months</time_frame>
    <description>Time to results from the inclusion of the trio (in days) specifying the time for each step (reception, sequencing, bioinformatics analysis, interpretation) (in days)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difficulties of interpretation of the exome sequencing in antenatal period</measure>
    <time_frame>13 months</time_frame>
    <description>Numbers of variants of unknown signification identified by exome sequencing with and without bioinformatic filters (targeted exome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of new genes responsible of fetal malformations</measure>
    <time_frame>13 months</time_frame>
    <description>If the results of CGH-array and targeted exome sequencing are negative, analysis of the entire exome sequencing to find new genes implicated in fetal development</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fetal Malformation</condition>
  <condition>Pregnancy Related</condition>
  <condition>Rare Genetic Disease</condition>
  <arm_group>
    <arm_group_label>90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CGH-array and exome sequencing</intervention_name>
    <description>A blood sample will be used for CGH-array and exome sequencing</description>
    <arm_group_label>90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Father and mother of an unborn child past the age of majority

          -  Consent dated and signed by the mother and by the father

          -  Father and mother able to understand the objectives and risks of the study

          -  For the mother, pregnancy in progress (between 12 and 34 weeks)

          -  For the mother, pregnancy with the presence of a malformation on ultrasound, confirmed
             by a doctor from the multidisciplinary diagnostic prenatal center, entering into the
             indications retained for this study

          -  Clinical validation of the couple's eligibility by an expert for some of selected
             indications

          -  Father and mother affiliated to a social protection health

        Exclusion Criteria:

          -  Identified genetic or chromosomal abnormality explaining the observed malformation

          -  Inability to give informations to the father and / or mother (father or mother in
             emergency or life-threatening situation)

          -  Father and / or mother under the protection of justice

          -  Father and / or mother under guardianship or curatorship

          -  Nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elise SCHAEFER</last_name>
    <phone>+33 3 88 12 81 20</phone>
    <email>elise.schaefer@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHu de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel VAN MALDERGEM</last_name>
      <phone>+33 3 81 21 81 87</phone>
      <email>lionel.van-maldergem@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel VAN MALDERGEM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette PIARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise BOUCHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christel THAUVIN</last_name>
      <phone>+33 3 80 29 53 13</phone>
      <email>Christel.thauvin@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Christel THAUVIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence FAIVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur SORLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien MOUTTON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Audrey PUTOUX</last_name>
      <phone>+33 4 27 85 50 83</phone>
      <email>Audrey.putoux@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Audrey PUTOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Region Mulhouse Et Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle GINGLINGER</last_name>
      <phone>+33 3 89 64 87 03</phone>
      <email>GINGLINGERE@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle GINGLINGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edgar MONTOYA RAMIREZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laetitia LAMBERT</last_name>
      <phone>+33 3 83 34 43 76</phone>
      <email>l.lambert@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Laetitia LAMBERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LEHEUP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandra AFENJAR</last_name>
      <phone>+33 1 44 73 61 86</phone>
      <email>Alexandra.afenjar@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra AFENJAR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Delphine HERON</last_name>
      <phone>+33 1 42 16 13 47</phone>
      <email>Delphine.heron@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine HERON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tania ATTIE-BITACH</last_name>
      <phone>+33 1 44 49 51 44</phone>
      <email>tania.attie@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Tania ATTIE-BITACH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martine DOCO-FENZY</last_name>
      <phone>+33 3 26 78 90 03</phone>
      <email>mdocofenzy@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Martine DOCO-FENZY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline POIRSIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvie ODENT</last_name>
      <phone>+33 2 99 26 67 44</phone>
      <email>Sylvie.odent@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie ODENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise SCHAEFER</last_name>
      <phone>+33 3 88 12 81 20</phone>
      <email>elise.schaefer@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Elise SCHAEFER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène DOLLFUS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima EL CHEHADEH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain FAVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent LAUGEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick CALVAS</last_name>
      <phone>+33 5 61 77 90 51</phone>
      <email>calvas.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick CALVAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fetal malformations</keyword>
  <keyword>Exome sequencing</keyword>
  <keyword>antenatal cerebral malformations</keyword>
  <keyword>antenatal ocular malformations</keyword>
  <keyword>antenatal large hyperechoic kidneys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

